Uncategorized
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.